The Tisch Cancer Institute

Discovery of the First-in-class Aurora B Kinase Selective Degrader sciencedirect.com/science/articl… Compound 18 effectively inhibits proliferation in multiple cancer cell lines. Jian Jin, PhD, @IcahnMountSinai and colleagues

New York Football Giants offensive lineman Bryan Hudson stopped by The Mount Sinai Hospital to help raise awareness about the urgent need for blood stem cell donors through the NMDP Registry. linkedin.com/posts/mountsin…

ajmc.com/view/linvoselt… via @AJMC #MultipleMyeloma @IcahnMountSinai

rsna.org/news/2025/july… @MargoliesLaurie @IcahnMountSinai talks about meeting the challenges in #BreastCancer screening access.

With New Treatment Strategies, a Cure for Multiple Myeloma Is Now Possible reports.mountsinai.org/article/tisch2… Sundar Jagannath @IcahnMountSinai discusses CARTITUDE-1 for #MultipleMyeloma

There's still time to register for gotoper.com/courses/live-m… @IcahnMountSinai faculty: John Mascarenhas, @JoshuaBrodyMD, @JoshuaRichterMD

Broad racial categories mask key cancer risks. Mount Sinai researchers call for disaggregated data to better detect GI cancer disparities in Asian American communities—and to advance more equitable care. bit.ly/44JjUqN @MountSinaiGI @ChristinaWangMD @J_YoonYoon

Pre-cystectomy ctDNA levels and metastatic recurrence in #BladderCancer patients. @ReubenBenDavid1 @IcahnMountSinai joins @zklaassen_md @GACancerCenter to discuss new research using Signatera to quantify ctDNA—not just detect it. 🔹 3 risk groups 🔹 Median progression: 5–12 mo…

New in @CellStemCell: TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via... sciencedirect.com/science/articl… @PapapetrouMDPhD @IcahnMountSinai and colleagues

Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise appliedclinicaltrialsonline.com/view/reblozyl-… via @appliedclinicaltrialsonline John Mascarehnhas, MD, says results show that Reblozyl can have an important impact on anemia associated with myelofibrosis.

From @BhardwajLab and colleagues: Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type I Dendritic Cells for Cancer Immunotherapy Applications pubmed.ncbi.nlm.nih.gov/40600891/ mountsinai.org/about/newsroom… @IcahnMountSinai #cancervaccine

From @AdamKittai and colleagues: International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations ashpublications.org/blood/article/…

Metabolism linked to protective effect of breastfeeding against breast cancer medicalxpress.com/news/2025-07-m… via @medical_xpress Doris Germain, PhD @IcahnMountSinai #breastcancer

Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells | Journal of Virology journals.asm.org/doi/10.1128/jv… From @fred_hirsch and colleagues #lungcancer

Study shows that benefit of breastfeeding for lowering #breastcancer risk depends on a woman’s metabolism and how her body responds to lactation at the cellular level. mountsinai.org/about/newsroom… Doris Germain, PhD, and colleagues report findings in @NatureComms @IcahnMountSinai

A New Vaccine Could Stop One of the Deadliest Forms of Breast Cancer Before It Starts via @@zmescience zmescience.com/medicine/a-new… @RimapatelMD at @IcahnMountSinai weighs in. #BreastCancerResearch

cancerletter.com/clinical-round…

Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research finance.yahoo.com/news/winn-cipp…

The FDA recently approved linvoseltamab for the treatment of relapsed or refractory multiple #myeloma. Hear @JoshuaRichterMD, of @TischCancer, talk about results of the LINKER-MM1 study that led to FDA approval. ➡️ buff.ly/2gLMfrb

Detecting, Monitoring Skin Cancers Made Easier with New Screening Technology - goo.gl/alerts/cmJDNz #GoogleAlert @IcahnMountSinai @MSHSDerm #skincancer